With TRAIL and TRAIL-receptor agonistic antibodies entering clinical trials for the treatment of patients with cancer [11], the question has arisen whether molecular markers can be identified, which would allow to select patients benefiting from such therapy. Here, TNFSF10 is linked to cancer.